In the news

Dr. Ken Stein, SVP and chief global medical officer, discusses the tremendous opportunities to use digital capabilities in medtech.

Dr. Janar Sathananthan, chief medical officer, Interventional Cardiology Therapies, discusses a new treatment option in the U.S. for patients with coronary artery disease who experience in-stent restenosis.

Wendy Carruthers, executive vice president of human resources, describes hybrid work as the best of both worlds with benefits for employees and employers alike.

Boston Scientific announced that it has entered into a definitive agreement to acquire Silk Road Medical, Inc., a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).

Boston Scientific announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System, the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP).

A presentation from WIRED Health 2024 discusses how Boston Scientific is advancing technologies to transform chronic pain care today and in the future.

The first coronary drug-coated balloon to be FDA-approved in the U.S., the Boston Scientific AGENT^TM Drug-Coated Balloon addresses a clinical unmet need by treating and preventing reoccurrence of in-stent restenosis in patients with coronary artery disease.

Boston Scientific shares how real-world data can help optimize physician decision making when treating patients with pulmonary embolism (PE).

Lisa Considine, vice president of human resources, and Adriana Gonzalez, director of global supply chain, share how Boston Scientific’s on-site day care in Marlborough, MA provides support and flexibility for employees while reinforcing an organizational culture of caring.

Next generation spinal cord stimulation devices, including Boston Scientific’s WaveWriter Alpha^TM SCS System, are providing relief to people living with diabetic peripheral neuropathy who are unresponsive to drugs or experience side effects.